Side Effect: Thrombocytopenia: Hematologic Adverse Effect of the COVID-19 Vaccine

Thrombocytopenia is a common and rare hematological but crucial adverse event following COVID-19 vaccination, such as, AstraZeneca and Johnson & Johnson with implications for disease severity and clinical outcomes. It can be distinguished by a low platelet count in the blood. This review explores the pathogenesis, clinical implications, and management strategies associated with thrombocytopenia in COVID-19 patients. The complex pathophysiology of COVID-19-associated thrombocytopenia is multifactorial and involves a combination of direct viral effects, immune-mediated mechanisms, endothelial dysfunction, and systemic inflammation. Thrombocytopenia can result from various factors, including bone marrow disorders, immune system disorders, infections, drug-induced liver diseases, and genetic disorders. Clinical features of vaccine-associated thrombocytopenia varied widely, ranging from asymptomatic thrombocytopenia to life-threatening thrombotic events, including cerebral venous sinus thrombosis (CVST) and disseminated intravascular coagulation (DIC). Diagnosis typically involves a complete blood count (CBC) to measure platelet levels and other blood cell counts and further tests to determine the underlying cause of thrombocytopenia. Timely recognition by understanding the underlying cause and management of vaccine-associated thrombocytopenia is essential to prevent complications and achieve desirable outcomes. Management of thrombocytopenia in COVID-19 entails providing supportive care and, in severe cases, considering therapeutic interventions such as platelet transfusions, immunomodulatory agents, anticoagulation therapy, immunosuppressive therapy, and lifestyle modifications to minimize the risk of bleeding complications. Continued surveillance, research, and communication efforts are needed to understand better the risk factors, pathogenesis, and optimal management of vaccine-associated thrombocytopenia. Clinicians should be vigilant for thrombocytopenia in COVID-19 patients and consider appropriate management strategies to mitigate the risk of thrombotic complications and improve patient outcomes.